CHATSWORTH, Calif.--(BUSINESS WIRE)--IRIS INTERNATIONAL, INC. (NASDAQ: IRIS) President and Chief Executive Officer César García told shareholders at the Annual Meeting today that the Company expects continued strong growth as it evolves into a broad-based cell morphology diagnostics company offering multiple new products in urinalysis, molecular diagnostics and hematology, with robust contributions from its existing core urinalysis product line and an expanding high profit consumables business.
